How has Rapport Therapeutics, Inc.'s other commercial liabilities changed year-over-year?

Rapport Therapeutics, Inc.'s other commercial liabilities increased by 39.8% year-over-year, from $6.24M to $8.72M.

What is the long-term trend for Rapport Therapeutics, Inc.'s other commercial liabilities?

Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s other commercial liabilities has grown at a 46.6% compound annual growth rate (CAGR), from $5.63M to $12.1M.

Rapport Therapeutics, Inc. RAPP Other Commercial Liabilities

Other Commercial Liabilities at other companies

Supernus PharmaceuticalsSUPN

——

Praxis Precision Medicines, Inc.PRAX

——

BiohavenBHVN

——

Septerna, Inc.SEPN

——

MapLight Therapeutics, Inc. MPLT

——

Acadia PharmaceuticalsACAD

——

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.91B+309%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s other commercial liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s other commercial liabilities?: Rapport Therapeutics, Inc. (RAPP) reported other commercial liabilities of $8.72M in Q1 2026.
How has Rapport Therapeutics, Inc.'s other commercial liabilities changed year-over-year?: Rapport Therapeutics, Inc.'s other commercial liabilities increased by 39.8% year-over-year, from $6.24M to $8.72M.
What is the long-term trend for Rapport Therapeutics, Inc.'s other commercial liabilities?: Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s other commercial liabilities has grown at a 46.6% compound annual growth rate (CAGR), from $5.63M to $12.1M.